Purpose: The pharmacokinetics, pharmacodynamics, and safety of pramlintide and various insulin formulations in patients with type 1 diabetes mellitus (DM) when given as separate injections or mixed in ...

In preterm infants, low levels of Insulin like growth factor 1 (IGF-I) have been associated with impaired growth and retinopathy of prematurity. Our objective was to study safety and pharmacokinetics ...

BUFFALO, N.Y. — When you pop a prescription pill into your mouth, you trust it to address the issue it was meant to fix. But what really happens? How is your body processing the drugs and what happens ...

Smoking has been shown to increase pulmonary permeability, and thereby to increase the absorption of inhaled insulin. To determine the effect of cessation and resumption of smoking on the time course ...

Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased incidence ...

Data Presented At European Diabetes Conference Demonstrate Biological Activity, Positive Safety Profile and Potential Dosing of Once Per Month or Longer ROME, Sep 8, 2008 -- XOMA Ltd. announced ...

Although there are numerous effective pharmacotherapeutic agents available to treat type 2 diabetes, 5% to 10% of the population with diabetes experience secondary failure. To help combat this issue, ...

WESTLAKE VILLAGE, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that the Afrezza® safety and pharmacokinetics study in pediatric patients is now ...

Severe insulin resistance syndrome was reported by the National Institute of Diabetes and Digestive and Kidney Diseases as early as 1975. 2 Severe insulin resistance is usually found in patients with ...

People with type 2 diabetes may be able to take pills or other non-insulin injections to manage their condition. Your doctor may also prescribe insulin if they determine that it might best help you ...

Lannett is one step closer to launching biosimilar insulin glargine. Recently, the company completed subject dosing in the pivotal clinical trial of biosimilar insulin glargine, a product being ...